Actinic (Solar) Keratosis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 92 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Actinic (Solar) Keratosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Actinic (Solar) Keratosis - Pipeline Review, H2 2014', provides an overview of the Actinic (Solar) Keratosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Actinic (Solar) Keratosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Actinic (Solar) Keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Actinic (Solar) Keratosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Actinic (Solar) Keratosis Overview 9
Therapeutics Development 10
Pipeline Products for Actinic (Solar) Keratosis - Overview 10
Pipeline Products for Actinic (Solar) Keratosis - Comparative Analysis 11
Actinic (Solar) Keratosis - Therapeutics under Development by Companies 12
Actinic (Solar) Keratosis - Therapeutics under Investigation by Universities/Institutes 14
Actinic (Solar) Keratosis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Actinic (Solar) Keratosis - Products under Development by Companies 19
Actinic (Solar) Keratosis - Products under Investigation by Universities/Institutes 20
Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development 21
Biofrontera AG 21
Galderma S.A. 22
LEO Pharma A/S 23
Clinuvel Pharmaceuticals Limited 24
3M Drug Delivery Systems 25
G&E Herbal Biotechnology Co., Ltd. 26
Paloma Pharmaceuticals, Inc. 27
Digna Biotech, S.L. 28
Foamix Ltd. 29
Kinex Pharmaceuticals, LLC 30
Promius Pharma, LLC 31
Genextra S.p.a. 32
Novelix Pharmaceuticals, Inc. 33
Advancell 34
Dolorgiet Gmbh & Co. Kg 35
Spherium biomed S.L. 36
Actinic (Solar) Keratosis - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
aminolevulinic acid hydrochloride - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
afamelanotide - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SRT-100 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
resiquimod - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AK-3012 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
DAC-0060 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AD-17137 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ACT-01 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
LEO-43204 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
disitertide - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
KX-01 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
P-529 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CUV-9900 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NVX-207 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ANS-401 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ANS-403 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
imiquimod - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
854-A - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Drug for Actinic Keratosis - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Ingenol Mebutate Analogs for Dermatology and Cancer - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
SP-12054 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Actinic (Solar) Keratosis - Recent Pipeline Updates 76
Actinic (Solar) Keratosis - Dormant Projects 82
Actinic (Solar) Keratosis - Discontinued Products 83
Actinic (Solar) Keratosis - Product Development Milestones 84
Featured News & Press Releases 84
Aug 20, 2014: Biofrontera files litigation against former supplier 84
Oct 21, 2013: Allergan launches Ameluz in Spain 84
Sep 20, 2013: Biofrontera: Actinic keratosis, most efficiently treated by Ameluz, recognized as occupational disease 85
Feb 19, 2013: Chugai Pharma Files Lawsuit On Patent Infringement Concerning Oxarol Ointment And Petition For Provisional Disposition Order 86
Jan 08, 2013: Biofrontera Receives Positive EMA Opinion On Extended Storage Conditions For Ameluz 86
Nov 05, 2012: Biofrontera Launches Ameluz In UK And Austria 87
Oct 15, 2012: Biofrontera And Bipharma Announce Launch Of Ameluz In Netherlands 88
Aug 13, 2012: Biofrontera Signs Distribution Agreement With Pelpharma For Marketing Of Ameluz In Austria 88
Jul 24, 2012: Biofrontera Signs Distribution Agreement With Spirit Healthcare For Marketing Ameluz In UK And Ireland 89
Jul 23, 2012: Biofrontera Discusses Approval Of Ameluz In US With FDA 89
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 92
Disclaimer 92

List of Tables
Number of Products under Development for Actinic (Solar) Keratosis, H2 2014 10
Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Comparative Analysis by Unknown Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Investigation by Universities/Institutes, H2 2014 20
Actinic (Solar) Keratosis - Pipeline by Biofrontera AG, H2 2014 21
Actinic (Solar) Keratosis - Pipeline by Galderma S.A., H2 2014 22
Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H2 2014 23
Actinic (Solar) Keratosis - Pipeline by Clinuvel Pharmaceuticals Limited, H2 2014 24
Actinic (Solar) Keratosis - Pipeline by 3M Drug Delivery Systems, H2 2014 25
Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2014 26
Actinic (Solar) Keratosis - Pipeline by Paloma Pharmaceuticals, Inc., H2 2014 27
Actinic (Solar) Keratosis - Pipeline by Digna Biotech, S.L., H2 2014 28
Actinic (Solar) Keratosis - Pipeline by Foamix Ltd., H2 2014 29
Actinic (Solar) Keratosis - Pipeline by Kinex Pharmaceuticals, LLC, H2 2014 30
Actinic (Solar) Keratosis - Pipeline by Promius Pharma, LLC, H2 2014 31
Actinic (Solar) Keratosis - Pipeline by Genextra S.p.a., H2 2014 32
Actinic (Solar) Keratosis - Pipeline by Novelix Pharmaceuticals, Inc., H2 2014 33
Actinic (Solar) Keratosis - Pipeline by Advancell, H2 2014 34
Actinic (Solar) Keratosis - Pipeline by Dolorgiet Gmbh & Co. Kg, H2 2014 35
Actinic (Solar) Keratosis - Pipeline by Spherium biomed S.L., H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Number of Products by Stage and Target, H2 2014 40
Number of Products by Stage and Mechanism of Action, H2 2014 43
Number of Products by Stage and Route of Administration, H2 2014 45
Number of Products by Stage and Molecule Type, H2 2014 47
Actinic (Solar) Keratosis Therapeutics - Recent Pipeline Updates, H2 2014 76
Actinic (Solar) Keratosis - Dormant Projects, H2 2014 82
Actinic (Solar) Keratosis - Discontinued Products, H2 2014 83